Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
2407268 | Vaccine | 2008 | 8 Pages |
Abstract
SummaryEscherichia coli O157:H7 produces Stx1 and Stx2 causing severe diseases. Their B subunits (StxBs) are useful for a vaccine but exhibit low immunogenicity, especially Stx2B. Nasal vaccination with StxBs plus cholera toxin induces only serum anti-Stx1B antibodies in mice. However, nasal administration of a mutant of E. coli enterotoxin and His-tagged Stx2B induced serum antibodies neutralizing Stx2 in vitro or in vivo and mucosal IgA antibodies in lungs. As His-tagged Stx2B showed five or three polymers in gel filtration chromatography, His-tagged Stx2B forms smaller tertiary structure than the native one and is effective for preventing Stx2 toxemia as a nasal vaccine.
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
Takao Tsuji, Takeshi Shimizu, Keiko Sasaki, Yoshiyasu Shimizu, Kentaro Tsukamoto, Hideyuki Arimitsu, Sadayuki Ochi, Satoshi Sugiyama, Koki Taniguchi, Paola Neri, Hiroshi Mori,